When Miriam and I started working on Covalenty, we knew we were focused on independent pharmacies in Brazil. But "independent pharmacy" as a category obscures a lot of internal variation. The owner-operated farmacia de bairro in a Sao Paulo neighborhood and the independent regional chain operating twenty stores in the interior of São Paulo state are both "independent" in the sense of not being affiliated with Raia Drogasil or Pague Menos. Their procurement situations, their regulatory burdens, and their operational challenges are quite different.
This article is an attempt to describe the market more precisely: who independent pharmacies in Brazil actually are, what the structural pressures they face look like, and why we think the procurement problem specifically is the right place to start.
The Scale of the Market
Brazil has a large retail pharmacy sector by global standards. The total number of registered pharmacy establishments is in the range of several tens of thousands, with a significant portion being independent operations that are not part of a national chain. The exact numbers shift as the CRF (Conselho Regional de Farmacia) and ANVISA records are updated, and any specific figure will be somewhat out of date by the time this is published. The directional point is that independent pharmacies are not a niche: they constitute a substantial share of the total pharmacy count in Brazil.
The national pharmacy chains, Raia Drogasil (which includes Droga Raia and Drogasil), Pague Menos, Farmacia Sao Joao, and a handful of others, dominate revenue and have been expanding their store footprint aggressively. The chain share of total pharmaceutical retail revenue has been growing for over a decade. But this consolidation has happened unevenly across geography: chains are concentrated in metropolitan areas, and independent pharmacies remain dominant in smaller cities, peri-urban neighborhoods, and rural areas where chain economics do not work.
The Independent Pharmacy Operator Profile
The modal independent pharmacy in Brazil is owner-operated. The proprietor is often the farmaceutico responsavel or works closely with one. Staff sizes typically range from two to eight people, including the owner. Monthly revenue is usually in the range that would qualify as a microempresa or empresa de pequeno porte under Brazilian tax frameworks.
Operations are lean. There is rarely a dedicated purchasing manager. The owner, the farmaceutico responsavel, or a senior pharmacy technician handles procurement as one part of a broader job. Accounting and fiscal management are typically outsourced to a contador. Technology adoption for back-office processes is variable: some independent pharmacies use pharmacy management software (sistemas de gestao farmaceutica) with reasonable depth; others track inventory in spreadsheets or rely heavily on physical paper records.
The credit profile is important for understanding how procurement works. Independent pharmacies typically pay distributors on 30 to 60 day terms, which requires maintaining good payment relationships with a small number of distributor partners. An independent pharmacy that has a payment dispute with its primary distributor is in a genuinely precarious position for restocking, which creates an asymmetric dependency that reinforces the loyalty dynamic we discussed in the pricing article.
The Competitive Pressure from Chains
The ongoing expansion of pharmacy chains creates a specific kind of competitive pressure on independents. Chains can offer lower consumer prices on some products because they buy at substantially better distributor prices on volume. They can run promotions and loyalty programs that individual independent pharmacies cannot easily replicate. They have brand recognition and national advertising budgets.
However, chains have structural weaknesses that independents can exploit. They are slower to serve non-standard patient needs. Their staff is more transient and less likely to build the kind of multi-year relationship with a specific patient cohort that many neighborhood farmaceuticos maintain. They are optimized for high-volume categories and are often poor at serving lower-volume specialty needs, compounded medications, or categories where the patient needs genuine pharmacist time rather than a fast transaction.
Independent pharmacies that compete primarily on price against chains are playing on the chain's strongest ground. The independents that are least vulnerable to chain competition are those that have differentiated on service, community relationship, or specialty categories. We are not saying price does not matter to these pharmacies: it matters for margins. But the strategic differentiator is not being cheapest, it is being the pharmacy where the neighborhood goes because of trust and service quality.
The Procurement Problem and Why It Is Particularly Acute for Independents
Pharmacy chains have centralized purchasing teams that manage distributor relationships, negotiate framework pricing, and maintain visibility across product categories and inventory levels. A chain's purchasing department is a professional function with dedicated staff and tools.
An independent pharmacy's purchasing is done by someone who also does ten other things. That person does not have time to maintain five distributor relationships, compare prices across all of them for every ordering cycle, and keep up with CMED updates, product classification changes, and ANVISA regulatory developments simultaneously. Something gives, and what typically gives is price optimization and broad distributor comparison.
This is not a failure of the people running independent pharmacies. It is a rational response to resource constraints. The question is whether technology can reduce the overhead of good procurement decision-making to the point where a person with limited time can still make well-informed purchasing decisions. That is what we are trying to answer with Covalenty.
Why We Focus on Sao Paulo First
We are starting in the greater São Paulo metropolitan area for straightforward reasons. It is one of the densest concentrations of independent pharmacies in Brazil. It has well-developed distributor infrastructure, which means distributor coverage on the platform is more achievable early. And it is where our team is based, which means we can do in-person conversations with pharmacy operators and distributor partners without the cost of travel.
The limitations of a São Paulo focus are real. A pharmacy in the interior of Minas Gerais or in the northeast of Brazil operates in a very different market with different distributor options and different regulatory enforcement patterns. We are not claiming that what we are building for São Paulo's independent pharmacies will automatically translate to those markets. We will need to understand each regional market on its own terms before claiming to serve it.
The reason to start concentrated rather than spread thin is that a marketplace that has ten distributors and three hundred active pharmacies in one city is more useful to those pharmacies than a marketplace that has two distributors and twenty pharmacies in each of twenty cities. Depth before breadth is the right strategy for a platform that needs transaction density to be valuable.
A Note on Data
Writing an accurate overview of the Brazilian independent pharmacy market is complicated by data limitations. ANVISA and CRF databases are not always up to date, the definition of "independent" varies by data source, and official statistics on the pharmaceutical retail market are collected and published with lags. The figures we work from internally are synthesized from multiple sources and should be treated as directional estimates rather than precise counts. We are not claiming this article is based on original research. It is based on our ongoing conversations with pharmacy operators and distributors, filtered through our direct experience of building a procurement product in this market since 2025.
